Last Updated: November 10, 2022: The Centers for Disease Control and Prevention (CDC) has reported a rapid increase in the circulation of certain SARS-CoV-2 Omicron subvariants in the United States that are likely to be resistant to currently used anti-SARS-CoV-2 monoclonal antibodies (mAbs).1
The subvariants BQ.1 and BQ.1.1 are likely to be resistant to bebtelovimab,2 and the subvariants BA.4.6, BA.2.75.2, BA.5.2.6, BF.7, BQ.1, and BQ.1.1 are likely to be resistant to tixagevimab plus cilgavimab (Evusheld).
The anticipated loss of susceptibility is based on knowledge about amino acid mutations that confer resistance to anti-SARS-CoV-2 antibodies and on data from in vitro neutralization studies.3
Source: Statement on Omicron Subvariants | COVID-19 Treatment Guidelines
